<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462280</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00896</org_study_id>
    <secondary_id>NCI-2009-00896</secondary_id>
    <secondary_id>2006-4937</secondary_id>
    <secondary_id>UCI03-1-01</secondary_id>
    <secondary_id>CDR0000540141</secondary_id>
    <secondary_id>UCI 06-06</secondary_id>
    <secondary_id>UCI03-1-01</secondary_id>
    <secondary_id>N01CN35160</secondary_id>
    <nct_id>NCT00462280</nct_id>
  </id_info>
  <brief_title>Lovastatin in Treating Patients At High Risk of Melanoma</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of lovastatin may slow disease progression in patients at high risk of melanoma. It
      is not yet known whether lovastatin is more effective than a placebo in treating patients at
      high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or
      placebo works in treating patients at high risk of melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the primary endpoint of the trial, by analysis of histopathologic regression
      of atypical nevi in response to a 6-month trial of oral (PO) lovastatin vs. placebo in
      subjects with atypical nevi.

      SECONDARY OBJECTIVES:

      I. To evaluate clinical regression of atypical nevi in the lovastatin vs. placebo group.

      II. To evaluate the secondary endpoint of changes in nevi numbers on subjects' backs in the
      lovastatin vs. placebo groups.

      III. To evaluate a number of molecular biomarkers as secondary endpoints in the lovastatin
      vs. placebo groups.

      IV. To evaluate the correlation of serum markers known to be affected by lovastatin with the
      endpoints chosen above.

      V. To evaluate the safety and tolerability of the dosing regimen, and the dose escalation.

      OUTLINE: Patients are randomized into 1 of 2 treatment arms per group.

      ARM I: Patients (with two matched nevi OR one large nevi) receive lovastatin PO once daily
      (QD) for up to 6 months in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients (with two matched nevi OR one large nevi) receive placebo PO QD for up to 6
      months in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>From close-up photos of target atypical nevi, lesions will be graded clinically. After unblinding of pre- or post-treatment status for photos, the grading score was as follows: 1= Post-treatment (Post-TX) photo shows a complete resolution of atypia relative to pre-treatment (Pre-TX) photo, 2 = Post-TX photo shows a strong lessening of atypia relative to Pre-TX photo, 3 = Post-TX photo shows a mild lessening of atypia relative to Pre-TX photo, 4 = Post-TX and Pre-TX photos show same degree of atypia, 5 = Pre-TX photo shows a mild lessening of atypia relative to Post-TX photo, 6 = Pre-TX photo shows a strong lessening of atypia relative to Post-TX photo, 7 = Pre-TX photo shows a complete resolution of atypia relative to Post-TX photo. The Wilcoxon rank sum test will be applied to compare the scores for patients treated with placebo vs. those treated with lovastatin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>Assessed by photos of subjects' back pre and post treatment. These photos will be used to count, by blinded evaluators, the number of nevi on the back pre and post therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation</measure>
    <time_frame>From baseline up to 24 weeks</time_frame>
    <description>Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cholesterol (mg/dL) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL (mg/dL) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL (mg/dL) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides (mg/dL) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SGOT/AST (U/L) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SGOT/ALT (U/L) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPK (U/L) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (mg/dL) From Baseline After Treatment</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least 1 Study-related Adverse Event Reported During the Study</measure>
    <time_frame>Baseline up to 26 weeks</time_frame>
    <description>All participants will be evaluable for toxicity from the time of their informed consent. Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Precancerous Condition</condition>
  <condition>Stage 0 Melanoma</condition>
  <condition>Stage I Melanoma</condition>
  <condition>Stage II Melanoma</condition>
  <arm_group>
    <arm_group_label>Two matched nevi group - Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two Matched Nevi Group - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One large nevi group - Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One Large Nevi Group - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lovastatin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Two matched nevi group - Lovastatin</arm_group_label>
    <arm_group_label>One large nevi group - Lovastatin</arm_group_label>
    <other_name>Lovastatin Sodium</other_name>
    <other_name>Mevacor</other_name>
    <other_name>Mevinolin</other_name>
    <other_name>Monacolin K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Two Matched Nevi Group - Placebo</arm_group_label>
    <arm_group_label>One Large Nevi Group - Placebo</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Two matched nevi group - Lovastatin</arm_group_label>
    <arm_group_label>Two Matched Nevi Group - Placebo</arm_group_label>
    <arm_group_label>One large nevi group - Lovastatin</arm_group_label>
    <arm_group_label>One Large Nevi Group - Placebo</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Two matched nevi group - Lovastatin</arm_group_label>
    <arm_group_label>Two Matched Nevi Group - Placebo</arm_group_label>
    <arm_group_label>One large nevi group - Lovastatin</arm_group_label>
    <arm_group_label>One Large Nevi Group - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least 2 clinically atypical nevi on the body that are reasonably
             matched in regards to level of clinical atypia, or one atypical mole and another
             atypical mole &gt;= 8 mm in diameter (for this pair the two moles do not have to be
             closely matched and only one of them must be &gt;= 8 mm in diameter)

          -  A history of melanoma is not required for study entry

          -  Patients with completely resected stage I or II who have not received adjuvant therapy
             in the past 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better (Karnofsky
             &gt; 70%)

          -  Leukocytes &gt;= 3,000/uL

          -  Absolute neutrophil count &gt;= 1,500/uL

          -  Platelets &gt;= 100,000/uL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
             =&lt; 2.5 X within normal limits

          -  Creatinine within normal institutional limits

          -  Ability to understand and the willingness to sign the written informed consent

          -  Subjects willing and able to participate for the full duration of the study

          -  For women of child-bearing potential (women are considered not of childbearing
             potential if they are at least 2 years post-menopausal and/or surgically sterile),
             she:

               -  has been using adequate contraception (abstinence, intrauterine device [IUD],
                  birth control pills, or spermicidal gel with diaphragm or condom) since her last
                  menses and will use adequate contraception during the study

               -  is not lactating, and

               -  has had a documented negative serum pregnancy test within 30 days prior to the
                  first dose of study medication Should a woman become pregnant or suspect she is
                  pregnant while participating in this study, she will be taken off study and be
                  advised to inform her treating physician immediately; a telephone follow-up with
                  the subject post-delivery will be completed to obtain outcome of pregnancy

          -  Men partnered with a female of child-bearing age must agree to use adequate
             contraception while on the study (i.e. abstinence, IUD, birth control pills, or
             spermicidal gel with diaphragm or condom)

        Exclusion Criteria:

          -  Subjects with untreated melanoma of any stage or locally advanced (&gt;= 4 mm in
             Breslow's thickness) or metastatic (stage III or IV) melanoma; subjects with melanoma
             may be considered for trial after complete resection of Stage I or II melanoma and
             those who have declined or are ineligible to go on any available adjuvant clinical
             trials known to the investigators or the subjects are eligible

          -  Subjects who are on adjuvant therapy or experimental therapy for melanoma currently or
             within the last 3 months prior to enrollment into this study

          -  Subjects currently or within the last three months before enrollment on lipid lowering
             agents of any type

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to lovastatin

          -  Clinically significant unrelated systemic illness

          -  Subjects with any medical or psychosocial condition that, in the opinion of the
             investigator, could jeopardize his/her participation in and compliance with the study

          -  Subjects may not be receiving any other investigational agents

          -  Pregnant or breast feeding females, or females of child bearing age not using a
             reliable method of contraception (use of lovastatin is contraindicated in pregnancy)

          -  Subjects who have been diagnosed with malignancies other than cutaneous melanoma,
             cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma within 5 years of
             study entry, unless they:

               -  are currently without evidence of disease

               -  have not received treatment for invasive malignancy in the last 6 months

               -  have no current or planned therapy, and

               -  have an expected disease-free survival of at least 5 years from study entry

          -  Chronic use of: itraconazole; ketoconazole; erythromycin; clarithromycin;
             telithromycin; human immunodeficiency virus (HIV) protease inhibitors; nefazodone;
             cyclosporine; gemfibrozil and other fibrates; danazol; amiodarone (amiodarone
             hydrochloride); verapamil; coumarin anticoagulants; niacin (nicotinic acid) (&gt;= 1
             g/day); or large quantities of grapefruit juice (&gt; l quart daily)

          -  Subjects with a history of coronary artery disease or stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Linden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Medical Center At Irvine-Orange Campus</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <results_first_submitted>April 23, 2014</results_first_submitted>
  <results_first_submitted_qc>October 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2014</results_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Two Matched Nevi Group - Lovastatin</title>
          <description>Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Two Matched Nevi Group - Placebo</title>
          <description>Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>One Large Nevi Group - Lovastatin</title>
          <description>Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P4">
          <title>One Large Nevi Group - Placebo</title>
          <description>Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Two Matched Nevi Group-Lovastatin</title>
          <description>Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Two Matched Nevi Group-Placebo</title>
          <description>Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>One Large Nevi Group-Lovastatin</title>
          <description>Patients with one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B4">
          <title>One Large Nevi Group-Placebo</title>
          <description>Patients with one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.82" spread="10.96"/>
                    <measurement group_id="B2" value="42.16" spread="11.28"/>
                    <measurement group_id="B3" value="45.71" spread="10.98"/>
                    <measurement group_id="B4" value="36.29" spread="11.98"/>
                    <measurement group_id="B5" value="42.24" spread="11.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation</title>
        <description>The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</population>
        <group_list>
          <group group_id="O1">
            <title>Two Matched Nevi Group - Lovastatin</title>
            <description>Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Two Matched Nevi Group - Placebo</title>
            <description>Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation</title>
          <description>The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</description>
          <population>Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="1.10"/>
                    <measurement group_id="O2" value="-0.12" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations</title>
        <description>From close-up photos of target atypical nevi, lesions will be graded clinically. After unblinding of pre- or post-treatment status for photos, the grading score was as follows: 1= Post-treatment (Post-TX) photo shows a complete resolution of atypia relative to pre-treatment (Pre-TX) photo, 2 = Post-TX photo shows a strong lessening of atypia relative to Pre-TX photo, 3 = Post-TX photo shows a mild lessening of atypia relative to Pre-TX photo, 4 = Post-TX and Pre-TX photos show same degree of atypia, 5 = Pre-TX photo shows a mild lessening of atypia relative to Post-TX photo, 6 = Pre-TX photo shows a strong lessening of atypia relative to Post-TX photo, 7 = Pre-TX photo shows a complete resolution of atypia relative to Post-TX photo. The Wilcoxon rank sum test will be applied to compare the scores for patients treated with placebo vs. those treated with lovastatin.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations</title>
          <description>From close-up photos of target atypical nevi, lesions will be graded clinically. After unblinding of pre- or post-treatment status for photos, the grading score was as follows: 1= Post-treatment (Post-TX) photo shows a complete resolution of atypia relative to pre-treatment (Pre-TX) photo, 2 = Post-TX photo shows a strong lessening of atypia relative to Pre-TX photo, 3 = Post-TX photo shows a mild lessening of atypia relative to Pre-TX photo, 4 = Post-TX and Pre-TX photos show same degree of atypia, 5 = Pre-TX photo shows a mild lessening of atypia relative to Post-TX photo, 6 = Pre-TX photo shows a strong lessening of atypia relative to Post-TX photo, 7 = Pre-TX photo shows a complete resolution of atypia relative to Post-TX photo. The Wilcoxon rank sum test will be applied to compare the scores for patients treated with placebo vs. those treated with lovastatin.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.26"/>
                    <measurement group_id="O2" value="3.98" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Nevus Number on Patient’s Back - Combined Three Reviewers' Evaluations</title>
        <description>Assessed by photos of subjects’ back pre and post treatment. These photos will be used to count, by blinded evaluators, the number of nevi on the back pre and post therapy.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm.
Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Total Nevus Number on Patient’s Back - Combined Three Reviewers' Evaluations</title>
          <description>Assessed by photos of subjects’ back pre and post treatment. These photos will be used to count, by blinded evaluators, the number of nevi on the back pre and post therapy.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>pairs of photos</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fewer nevi after the treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Same number of nevi after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More nevi after the treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation</title>
        <description>HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation</title>
          <description>HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.13" upper_limit="0.22"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-0.75" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation</title>
        <description>(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation</title>
          <description>(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="-7.29" upper_limit="8.63"/>
                    <measurement group_id="O2" value="-7.37" lower_limit="-20.60" upper_limit="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation</title>
        <description>The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</population>
        <group_list>
          <group group_id="O1">
            <title>Two Matched Nevi Group - Lovastatin</title>
            <description>Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Two Matched Nevi Group - Placebo</title>
            <description>Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation</title>
          <description>The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</description>
          <population>Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.81"/>
                    <measurement group_id="O2" value="0.04" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation</title>
        <description>(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation</title>
          <description>(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.91" lower_limit="-15.85" upper_limit="27.67"/>
                    <measurement group_id="O2" value="-9.17" lower_limit="-20.74" upper_limit="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation</title>
        <description>VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation</title>
          <description>VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="-11.92" upper_limit="21.55"/>
                    <measurement group_id="O2" value="-0.63" lower_limit="-17.89" upper_limit="16.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation</title>
        <description>RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation</title>
          <description>RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="-1.00" upper_limit="2.67"/>
                    <measurement group_id="O2" value="-1.25" lower_limit="-6.26" upper_limit="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation</title>
        <description>p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation</title>
          <description>p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-13.09" upper_limit="15.09"/>
                    <measurement group_id="O2" value="1.18" lower_limit="-10.59" upper_limit="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation</title>
        <description>Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation</title>
          <description>Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="-1.48" upper_limit="2.94"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-0.39" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation</title>
        <description>HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation</title>
          <description>HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.13" upper_limit="0.05"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.12" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation</title>
        <description>(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation</title>
          <description>(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" lower_limit="-6.72" upper_limit="15.17"/>
                    <measurement group_id="O2" value="-7.40" lower_limit="-20.10" upper_limit="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation</title>
        <description>(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation</title>
          <description>(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="-11.64" upper_limit="20.11"/>
                    <measurement group_id="O2" value="-3.52" lower_limit="-9.45" upper_limit="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation</title>
        <description>VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation</title>
          <description>VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" lower_limit="-8.08" upper_limit="4.43"/>
                    <measurement group_id="O2" value="-2.24" lower_limit="-10.10" upper_limit="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation</title>
        <description>RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation</title>
          <description>RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" lower_limit="-2.34" upper_limit="9.79"/>
                    <measurement group_id="O2" value="-3.44" lower_limit="-10.98" upper_limit="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation</title>
        <description>p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation</title>
          <description>p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="-3.48" upper_limit="7.58"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-3.42" upper_limit="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation</title>
        <description>Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
        <time_frame>From baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation</title>
          <description>Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>percentage of cells that are positive</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="-0.81" upper_limit="1.96"/>
                    <measurement group_id="O2" value="0.28" lower_limit="-0.43" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cholesterol (mg/dL) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cholesterol (mg/dL) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.25" lower_limit="-38.32" upper_limit="-16.18"/>
                    <measurement group_id="O2" value="-3.77" lower_limit="-16.43" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL (mg/dL) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL (mg/dL) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.28" lower_limit="-35.6" upper_limit="-14.96"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-12.54" upper_limit="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL (mg/dL) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL (mg/dL) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" lower_limit="-5.19" upper_limit="2.36"/>
                    <measurement group_id="O2" value="-2.63" lower_limit="-8.34" upper_limit="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides (mg/dL) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides (mg/dL) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="-8.67" upper_limit="11.1"/>
                    <measurement group_id="O2" value="1.65" lower_limit="-20.3" upper_limit="23.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SGOT/AST (U/L) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SGOT/AST (U/L) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" lower_limit="-0.73" upper_limit="7.57"/>
                    <measurement group_id="O2" value="-0.75" lower_limit="-3.43" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SGOT/ALT (U/L) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SGOT/ALT (U/L) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" lower_limit="-0.5" upper_limit="11.72"/>
                    <measurement group_id="O2" value="2.93" lower_limit="-1.17" upper_limit="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CPK (U/L) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CPK (U/L) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.94" lower_limit="-2.21" upper_limit="44.08"/>
                    <measurement group_id="O2" value="9.1" lower_limit="-18.76" upper_limit="36.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein (mg/dL) From Baseline After Treatment</title>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (mg/dL) From Baseline After Treatment</title>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. The total number of participants who have complete data are analyzed in this outcome measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.96" upper_limit="0.37"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-0.26" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least 1 Study-related Adverse Event Reported During the Study</title>
        <description>All participants will be evaluable for toxicity from the time of their informed consent. Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.</description>
        <time_frame>Baseline up to 26 weeks</time_frame>
        <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin</title>
            <description>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm. Patients received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm. Patients received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>At Least 1 Study-related Adverse Event Reported During the Study</title>
          <description>All participants will be evaluable for toxicity from the time of their informed consent. Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.</description>
          <population>One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the &quot;Lovastatin&quot; arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the &quot;Placebo&quot; arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The onset date of adverse event is between the randomization date and the date of off-study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Two Matched Nevi Group-Lovastatin</title>
          <description>Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Two Matched Nevi Group-Placebo</title>
          <description>Patients receive placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E3">
          <title>One Large Nevi Group-Lovastatin</title>
          <description>Patients who have one large nevi received lovastatin PO QD for up to 6 months</description>
        </group>
        <group group_id="E4">
          <title>One Large Nevi Group-Placebo</title>
          <description>Patients who have one large nevi receive placebo PO QD for up to 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELEVATED CPK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ROTATOR CUFF SURGERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HIGH BLOOD PRESSURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISUAL DISTURBANCES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACID REFLUX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>BLOATING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COLPOSCOPY-STOMACH DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CONSTIPATION( INTERMITTANT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CRAMPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>GAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HEARTBURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INDIGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INTERMITTENT NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LOOSE STOOLS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MOTION SICKNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ROOT CANAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SOFT STOOLS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>STOMACH ACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>STOMACH DISCOMFORT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>STOMACH PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>STOMACH UPSET</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>STOMACH UPSET/GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TEETH SENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TOOTH PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>WISDOM TEETH EXTRACTION - TOOTH PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>COLD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COLD SYMPTOMS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COLD-FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FLU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FLU-FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TIRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BIOPSY SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COMMON COLD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SINUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>YEAST INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT SGPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>AST SGOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CPK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED BILIRUBIN LEVEL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED CPK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED CREATINE KINASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED LDH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED TOTAL CK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED TRIGLYCERIDES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HIGH CHOLESTEROL LEVEL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>JOINT PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>JOINT/BONE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LEFT HIP PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LEFT HIP SENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LOWER BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE ACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE CRAMPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE CRAMPS/PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE PAIN - NECK, BACK, SHOULDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE PAIN AND ACHES;</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCLE TWITCHES IN THE UPPER LEFT ARM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NECK PAIN-ARTHRITIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NEW FOOT PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PAIN LOWER BACK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PAIN-SHOULDER MUSCLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PULLED BACK - LUMBAR SPINE INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PULLED TENDON</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>RIB PAIN - INTERMITTENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>RIGHT HIP PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>RIGHT KNEE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>RIGHT LEG WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SHOULDER PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SORE BACK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SORE CALF MUSCLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SPRAINED FINGER-PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SWOLLEN ANKLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>UNKNOWN CHANGE IN THE CERVICAL LYMPH NODE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ARMS TINGLING AT NIGHT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DIZZINESS - INTERMITTENT - 2-3 TIMES A WEEK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LIGHTHEADEDNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NUMBNESS AND SHOOTING PAIN IN LOWER BACK AND LEGS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NUMBNESS AND TINGLING IN THE RIGHT ARM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NERVOUS SYSTEM ( PARESTHESIA) TINGLING SKIN- LEFT SIDE FACE.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PNS LEFT HAND PARESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TINGLING IN R PALM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TINGLING IN R THUMB &amp; R INDEX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TINGLING IN THE FEET</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>UNKNOWN PERIPHERAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED LIBIDO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INTERMITTENT INSOMNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>EXTRA URINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST TENDERNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FIBROIDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MENSTRUAL CRAMPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PAIN IN BREASTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>PHARYNIGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>STREP THROAT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>3 NEW MOLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ATYPICAL MOLE BIOPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COLD SORE OUTBREAK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DRY FINGER TIPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FACELIFT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FEVER SORE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HIVES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ITCHY AT BIOPSY SITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ITCHY HAND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MOLE CHANGE, FATTER AND LIGHTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MOLE ON NECK CHANGE IN APPEARANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MOLE REMOVAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MOLES (2) BIOPSIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SCALY MOLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SEBORRHEIC KERATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SHINGLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN REACTION TO BANDAID ADHESIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN TAG CHANGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SLIGHTLY ATYPICAL LENTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SUNBURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth G. Linden</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>714-456-3719</phone>
      <email>kglinden@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

